38O - PD-L1 and PD-1 expression in molecularly selected non-small-cell lung cancer (NSCLC) patients
|Date||27 March 2014|
|Session||Proffered Papers 2 - Tumour biology and translational research|
|Topics|| Lung and other Thoracic Tumours
|Citation||Journal of Thoracic Oncology (2014) 9 (Supplement 9): S7-S52. 10.1097/JTO.0000000000000131|
A. D'Incecco1, M. Andreozzi2, V. Ludovini3, E. Rossi4, L. Landi5, G. Minuti5, G. Fontanini6, L. Crinò3, L. Terracciano2, F. Cappuzzo5
The programmed death 1 (PD-1) receptor is an inhibitory T-cell receptor with two known ligands, PD-L1 and PD-L2 (programmed death-ligand 1 and 2). Aim of the present study was to evaluate PD-L1 and PD-1 expression in a cohort of molecularly selected NSCLC patients.